Merck posts better-than-expected second-quarter results on Keytruda strength

By Michael Erman and Christy Santhosh

Aug 4 (Reuters) - Merck reported higher-than-expected second-quarter income connected Tuesday and raised its full-year gross forecast connected the spot of its top-selling crab attraction Keytruda.

The U.S. drugmaker reported quarterly gross ‌of $16.61 billion, up 5% from a twelvemonth earlier and supra analysts' mean estimation of $16.36 billion, according to LSEG ‌data.

Merck reported a nonaccomplishment for the 4th owed to a $5.7 cardinal complaint from its acquisition of crab cause developer Terns Pharmaceuticals.

The company's reported nonaccomplishment successful the ​quarter was 13 cents per share, including the $2.31 per stock complaint from the deal. Analysts had expected a larger adjusted nonaccomplishment per stock of 27 cents, and Merck shares roseate 0.6% to $128.54 successful aboriginal trading.

Sales of immunotherapy Keytruda, the world's top-selling medicine medicine, roseate 5% to $8.37 cardinal successful the quarter, including $463 cardinal from its newer subcutaneous formulation, Keytruda QLEX. That exceeded analysts' estimation of $8.07 billion.

CEO Rob ‌Davis said the loss-of-exclusivity play for Keytruda ⁠would beryllium "more of a elevation than a cliff," with a shallow dip followed by a accelerated instrumentality to growth.

Keytruda is acceptable to suffer cardinal patent protections starting successful 2028, exposing the institution to ⁠competition from perchance little costly biosimilar versions of the drug, though different drugmakers person maintained ample marketplace shares erstwhile faced with biosimilars.

Stronger-than-expected QLEX uptake contributed to the Keytruda beat, Chief Financial Officer Caroline Litchfield said successful an interview.

"We're astatine double-digit of QLEX arsenic a information ​of ​the full concern successful the United States, and we are precise overmuch ​on a way that takes america to the ‌30% to 40% adoption by the extremity of 2027," she said.

Gardasil, Merck's cancer-preventing HPV vaccine, generated income of $1.17 billion, somewhat supra the $1.15 cardinal expert consensus.

Sales of its measles, mumps, rubella and chickenpox vaccines fell 3% to $592 cardinal successful the quarter, beneath analysts' estimates of $608 million. The institution said the diminution was owed chiefly to little U.S. demand.

"The information that we entree suggest that the wide vaccines marketplace successful the United States has declined," Litchfield said, adding that the premix of vaccines the institution makes ‌is faring rather good wrong that declining market.

Animal wellness income roseate 8% ​to $1.78 billion, somewhat up of Wall Street projections of $1.75 billion.

Separately, Merck said ​its experimental drug, tulisokibart, met the main extremity successful ​a mid-stage proceedings for hidradenitis suppurativa, an inflammatory tegument condition, but failed successful different proceedings involving patients ‌with a benignant of lung disease.